SEC Comment Letter 0000000000-22-013181 to FENNEC PHARMACEUTICALS INC. (FENC) (CIK 0001211583) (FENC)
FENNEC PHARMACEUTICALS INC. (FENC) (CIK 0001211583)
Date: Dec. 7, 2022 · CIK: 0001211583 · Accession: 0000000000-22-013181
AI Filing Summary & Sentiment
File numbers found in text: 333-268632
Letter
United States securities and exchange commission logo December 7, 2022 Rostislav Raykov Chief Executive Officer Fennec Pharmaceuticals Inc. PO Box 13628, 68 TW Alexander Drive Research Triangle Park, NC 27709 Re:Fennec Pharmaceuticals Inc. Registration Statement on Form S-3 Filed December 1, 2022 File No. 333-268632 Dear Rostislav Raykov: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Garett Sleichter, Esq.
Show Raw Text
United States securities and exchange commission logo
December 7, 2022
Rostislav Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
PO Box 13628, 68 TW Alexander Drive
Research Triangle Park, NC 27709
Re:Fennec Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed December 1, 2022
File No. 333-268632
Dear Rostislav Raykov:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Garett Sleichter, Esq.